The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
Condition(s):Resectable Pancreatic Ductal AdenocarcinomaLast Updated:January 18, 2018Unknown status
Hide Studies Not Open or Pending
Condition(s):Resectable Pancreatic Ductal AdenocarcinomaLast Updated:January 18, 2018Unknown status
Condition(s):HealthyLast Updated:November 25, 2019Completed
Condition(s):Diabetes Mellitus, Type 2; Metformin Adverse ReactionLast Updated:December 5, 2017Completed
Condition(s):Fragile X SyndromeLast Updated:February 4, 2021Completed
Condition(s):Type 2 Diabetes MellitusLast Updated:June 28, 2021Completed
Condition(s):Oral CancerLast Updated:September 26, 2018Unknown status
Condition(s):Osteosarcoma; Ewing SarcomaLast Updated:March 30, 2021Recruiting
Condition(s):Type 1 Diabetes Mellitus; MetforminLast Updated:July 20, 2018Unknown status
Condition(s):Preeclampsia; Preeclampsia Severe; High Risk Pregnancy; EclampsiaLast Updated:March 29, 2022Not yet recruiting
Condition(s):Glioma; Cholangiocarcinoma; ChondrosarcomaLast Updated:January 9, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.